KFRX 03
Alternative Names: BK 40143; KFRX-03Latest Information Update: 09 Sep 2024
Price :
$50 *
At a glance
- Originator KeifeRx
- Class Antibacterials; Antineoplastics; Small molecules
- Mechanism of Action Protein tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alzheimer's disease; Amyotrophic lateral sclerosis; Lyme disease; Mastocytosis
Most Recent Events
- 09 Sep 2024 Preclinical trials in Alzheimer's disease in USA (PO) prior to September 2024 (keiferx pipeline, September 2024)
- 29 Mar 2023 Preclinical trials in Amyotrophic lateral sclerosis in USA (PO) (keiferx pipeline, March 2023)
- 29 Mar 2023 Preclinical trials in Lyme disease in USA (PO) (keiferx pipeline, March 2023)